Epizootic hemorrhagic disease virus—tel aviv university (EHDV-TAU)—oncolytic virus for treating cancer
US11484558B2 · kind B2 · utility
0Cited by
0References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 26, 2018 |
| Grant date | Nov 1, 2022 |
| Priority date | — |
| Expiry date | Jan 28, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2720/12171
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a unique oncolytic virus, Epizootic Hemorrhagic Disease virus-Tel Aviv University (EHDV-TAU), and to methods and pharmaceutical compositions comprising thereof for preventing or treating cancer exhibiting an alteration in interferon signaling and/or the innate immune antiviral response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.